Metabolic SyndromeNCT01688622
Glypican4 and CTRP5 in Metabolic Syndrome and the Effect of Exercise on These Adipokines
A study testing 3months Exercise in people with Metabolic Syndrome and Obesity, run by Korea University at 1 site in South Korea.
Trial summary
Glypican4, CTRP3, CTRP5 are emerging novel adipokines mediating obesity and inflammation related disorders. RBP4 and adiponectin are well known important adipokines. Therefore, we examine the circulating levels of theses adipokines in the subjects with or without metabolic syndrome. Read more about this study
- Who is it for?
- Ages 20 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Metabolic Syndrome, Obesity
- What is being tested?
- 3months Exercise
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteSouth Korea
- Study dates
- Jul 2012to Sep 2012
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Women between 30 and 60 years of age who had a body mass index (BMI) more than 25 kg/m2
- The subjects of metabolic syndrome and age, gender matched non metabolic syndrome among the participants of Korean SO Study (KSOS) study, which is an ongoing epidemiologic study supported by the Korea Science and Engineering Foundation
Who cannot join
- participants had a history of cardiovascular disease
- any type of diabetes
- stage 2 hypertension
- malignant disease, severe renal, or hepatic disease
- Subjects taking medications that might affect body weight or body composition
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effects of Exercise on Glypican4,CTRP3,5 and RBP4 Levels and Circulating Levels of These Adipokines in the Subjects With or Without Metabolic Syndrome
Glypican4, CTRP3, CTRP5 are emerging novel adipokines mediating obesity and inflammation related disorders. RBP4 and adiponectin are well known important adipokines. Therefore, we examine the circulating levels of theses adipokines in the subjects with or without metabolic syndrome. Furthermore, we tried to clarify the effect of exercise on the circulating these adipokines.
- Conditions
- Metabolic Syndrome, Obesity
- Being tested
- 3months Exercise
- Medical subject headings
- Metabolic Syndrome, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
3months ExerciseBehavioural
training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.
| Study group | Role | What they receive |
|---|---|---|
| Exercise | Other | obese women who are volunteers for the 3 months exercise programs Receives: Behavioral: 3months Exercise |
What is being measured
The primary outcome is the main question the study is designed to answer.
The changes of circulating glypican4 levels after 3 months exercise
Measured: baseline and 12weeks
The changes of circulating CTRP3 levels after 3 months exercise
Measured: baseline and 12weeks
The changes of circulating CTRP5 levels after 3 months exercise
Measured: baseline and 12weeks
The changes of circulating RBP4 levels after 3 months exercise
Measured: baseline and 12weeks
The changes of circulating adiponectin levels after 3 months exercise
Measured: baseline and 12weeks
Secondary outcomes (5)
Circulating glypican4 levels in the subjects with or without metabolic syndrome
Measured: baseline
Circulating CTRP3 levels in the subjects with or without metabolic syndrome
Measured: baseline
Circulating CTRP5 levels in the subjects with or without metabolic syndrome
Measured: baseline
Circulating RBP4 levels in the subjects with or without metabolic syndrome
Measured: baseline
Circulating adiponectin levels in the subjects with or without metabolic syndrome
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Sep 2012 (estimated)
- Study startJul 2012
- Primary completionSep 2012
- Study completionSep 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Metabolic SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Korea University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, K. M. Choi, Korea University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01688622
- Sponsor's protocol ID
- KoreaSO_Exercise
- Status last verified
- Sep 2012
- First submitted
- 13 Sep 2012
- Last updated
- 21 Sep 2012
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Choi HY, Park JW, Lee N, Hwang SY, Cho GJ, Hong HC, Yoo HJ, Hwang TG, Kim SM, Baik SH, Park KS, Youn BS, Choi KM. Effects of a combined aerobic and resistance exercise program on C1q/TNF-related protein-3 (CTRP-3) and CTRP-5 levels. Diabetes Care. 2013 Oct;36(10):3321-7. doi: 10.2337/dc13-0178. Epub 2013 Jun 18.
PubMed 23780948Yoo HJ, Hwang SY, Cho GJ, Hong HC, Choi HY, Hwang TG, Kim SM, Bluher M, Youn BS, Baik SH, Choi KM. Association of glypican-4 with body fat distribution, insulin resistance, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2013 Jul;98(7):2897-901. doi: 10.1210/jc.2012-4297. Epub 2013 Apr 30.
PubMed 23633195
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Exercise on Glypican4,CTRP3,5 and RBP4 Levels and Circulating Levels of These Adipokines in the Subjects With or Without Metabolic Syndrome
- ClinicalTrials.gov ID
- NCT01688622
- Acronym / sponsor ID
- KoreaSO_Exercise
- Conditions
- Metabolic Syndrome, Obesity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Korea UniversityUniversity, hospital or other
- Study start
- Jul 2012
- Primary completion
- Sep 2012 (actual)
- Study completion
- Sep 2012 (actual)
- First posted
- 20 Sep 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Glypican4, CTRP3, CTRP5 are emerging novel adipokines mediating obesity and inflammation related disorders. RBP4 and adiponectin are well known important adipokines. Therefore, we examine the circulating levels of theses adipokines in the subjects with or without metabolic syndrome. Furthermore, we tried to clarify the effect of exercise on the circulating these adipokines.
Study design
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Exercise | Other | Behavioral: 3months Exerciseobese women who are volunteers for the 3 months exercise programs |
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Women between 30 and 60 years of age who had a body mass index (BMI) more than 25 kg/m2
- The subjects of metabolic syndrome and age, gender matched non metabolic syndrome among the participants of Korean SO Study (KSOS) study, which is an ongoing epidemiologic study supported by the Korea Science and Engineering Foundation
Key exclusion criteria (5 listed)
- participants had a history of cardiovascular disease
- any type of diabetes
- stage 2 hypertension
- malignant disease, severe renal, or hepatic disease
- Subjects taking medications that might affect body weight or body composition
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 3months Exercisetraining session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period. | Behavioural | Exercise |
Primary outcome
The changes of circulating glypican4 levels after 3 months exercise
Time frame: baseline and 12weeks
The changes of circulating CTRP3 levels after 3 months exercise
Time frame: baseline and 12weeks
The changes of circulating CTRP5 levels after 3 months exercise
Time frame: baseline and 12weeks
The changes of circulating RBP4 levels after 3 months exercise
Time frame: baseline and 12weeks
The changes of circulating adiponectin levels after 3 months exercise
Time frame: baseline and 12weeks
5 secondary outcomes
Circulating glypican4 levels in the subjects with or without metabolic syndrome
Time frame: baseline
Circulating CTRP3 levels in the subjects with or without metabolic syndrome
Time frame: baseline
Circulating CTRP5 levels in the subjects with or without metabolic syndrome
Time frame: baseline
Circulating RBP4 levels in the subjects with or without metabolic syndrome
Time frame: baseline
Circulating adiponectin levels in the subjects with or without metabolic syndrome
Time frame: baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2012.
- Derived from this study: PubMed 23780948Choi HY, Park JW, Lee N, Hwang SY, Cho GJ, Hong HC, Yoo HJ, Hwang TG, Kim SM, Baik SH, Park KS, Youn BS, Choi KM. Effects of a combined aerobic and resistance exercise program on C1q/TNF-related protein-3 (CTRP-3) and CTRP-5 levels. Diabetes Care. 2013 Oct;36(10):3321-7. doi: 10.2337/dc13-0178. Epub 2013 Jun 18.
- Derived from this study: PubMed 23633195Yoo HJ, Hwang SY, Cho GJ, Hong HC, Choi HY, Hwang TG, Kim SM, Bluher M, Youn BS, Baik SH, Choi KM. Association of glypican-4 with body fat distribution, insulin resistance, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2013 Jul;98(7):2897-901. doi: 10.1210/jc.2012-4297. Epub 2013 Apr 30.
Related trials for Metabolic Syndrome
RecruitingObservational study
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
Not yet recruitingPhase 2
Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Mild Autonomous Cortisol Secretion (MACS), Diabetes Mellitus (Type 2)
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 3months Exercise in people with Metabolic Syndrome and Obesity, run by Korea University at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Sep 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The changes of circulating glypican4 levels after 3 months exercise (time frame: baseline and 12weeks). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01688622, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2012; AzTrials last refreshed its copy on 8 Nov 2026.